Isofol Medical AB (ISOFOL) Price & Analysis

Compare

1 Followers

ISOFOL Stock Chart & Stats

kr0.72

-kr0.10(-6.34%)

At close: Mar 06 4:00 PM EST

kr0.72

-kr0.10(-6.34%)

Day’s Range― - ―

52-Week Rangekr0.55 - kr2.14

Previous CloseN/A

Volume134.77K

Average Volume (3M)501.89K

Market Cap

kr185.11M

Enterprise Valuekr143.12M

Total Cash (Recent Filing)kr126.99M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.49

Next Earnings

May 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding281,107,240

10 Day Avg. Volume847,726

30 Day Avg. Volume501,890

Financial Highlights & Ratios

PEG Ratio0.39

Price to Book (P/B)1.46

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.2

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Debt-free Balance SheetA debt-free balance sheet materially reduces solvency risk and interest burden over the next several quarters. This structural strength preserves strategic optionality for timing of partnerships or financing, allowing management to prioritize clinical milestones without heavy fixed financing costs.

Improved Cash Burn Vs Earlier YearsSustained reduction in operating cash burn demonstrates improved cost control and more efficient clinical spending. This durable improvement extends runway per financing round, lowers near-term dilution risk, and increases the probability of reaching regulatory or partnering inflection points.

Focused Clinical-stage Pipeline And Partnering StrategyA focused, single-asset clinical strategy concentrates resources on a clear regulatory and partnering path. This business model reduces commercial infrastructure needs, accelerates decision-making, and makes the company an attractive, lower-cost partner for larger oncology players seeking to license or co-develop.

Bears Say

No Recent Revenue / Pre-commercial ProfileLack of revenue is a structural constraint: the company cannot self-fund development through product cash flows. Over a multi-month horizon this maintains reliance on external capital, increasing execution risk if markets or partner interest softens and reducing internal flexibility.

Persistent Net Losses And Ongoing Cash BurnLarge recurring losses and material negative operating cash flow deplete resources and mandate further financing unless clinical progress changes economics. Persistent burn pressures management to prioritize rounds or deals that may be dilutive or constrain long-term strategic choices.

Eroding Equity Base And Funding DependenceSignificant equity erosion signals accumulated losses and reduces the balance-sheet cushion against setbacks. Over months this raises dilution risk and could weaken bargaining power with partners or investors, making future financings more costly or restrictive for long-term plans.

Isofol Medical AB News

Isofol Sets TO1 Warrant Price and Exercise Window, Targets SEK 19 Million Raise

Isofol Medical AB ( ($SE:ISOFOL) ) has issued an update. Isofol Medical has set the subscription price for...

4d ago

Isofol Secures Stakeholder Support Covering 42% of Upcoming TO1 Warrant Exercise

The latest update is out from Isofol Medical AB ( ($SE:ISOFOL) ). Isofol Medical has secured a top...

6d ago

Isofol to Add Major Shareholder Christian Haglund to Expanded Board

An update from Isofol Medical AB ( ($SE:ISOFOL) ) is now available. Isofol’s nomination committee has proposed the...

8d ago

Isofol to Showcase Cancer Drug Candidate at Key March Investor Events

Isofol Medical AB ( ($SE:ISOFOL) ) has shared an announcement. Isofol Medical AB, listed on Nasdaq Stockholm, develops...

14d ago

Isofol Reports Strong Early Data for Arfolitixorin in Difficult-to-Treat Colorectal Cancer

The latest update is out from Isofol Medical AB ( ($SE:ISOFOL) ). Isofol Medical has reported encouraging interim...

21d ago

Isofol strengthens arfolitixorin program with new EU patent and advancing trials

An update from Isofol Medical AB ( ($SE:ISOFOL) ) is now available. Isofol Medical AB continued development of...

27d ago

Isofol Showcases Arfolitixorin Trial Design at ASCO GI as Phase Ib/II Study Advances

Isofol Medical AB ( ($SE:ISOFOL) ) has issued an announcement. Isofol Medical AB will participate in the ASCO...

2M ago

Isofol Medical to Showcase Arfolitixorin at Upcoming Investor Meetings

An update from Isofol Medical AB ( ($SE:ISOFOL) ) is now available. Isofol Medical AB announced its participation...

4M ago

Isofol Medical Secures New Patent for Cancer Drug Candidate Arfolitixorin

Isofol Medical AB ( ($SE:ISOFOL) ) just unveiled an update. Isofol Medical AB announced that the European Patent...

4M ago

Isofol Medical AB Reports Key Developments in Interim Report

An update from Isofol Medical AB ( ($SE:ISOFOL) ) is now available. Isofol Medical AB has released its...

4M ago

ISOFOL FAQ

What was Isofol Medical AB’s price range in the past 12 months?

Isofol Medical AB lowest stock price was kr0.55 and its highest was kr2.14 in the past 12 months.

What is Isofol Medical AB’s market cap?

Isofol Medical AB’s market cap is kr185.11M.

When is Isofol Medical AB’s upcoming earnings report date?

Isofol Medical AB’s upcoming earnings report date is May 19, 2026 which is in 63 days.

How were Isofol Medical AB’s earnings last quarter?

Isofol Medical AB released its earnings results on Feb 18, 2026. The company reported -kr0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.05.

Is Isofol Medical AB overvalued?

According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Isofol Medical AB pay dividends?

Isofol Medical AB does not currently pay dividends.

What is Isofol Medical AB’s EPS estimate?

Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Isofol Medical AB have?

Isofol Medical AB has 281,107,240 shares outstanding.

What happened to Isofol Medical AB’s price movement after its last earnings report?

Isofol Medical AB reported an EPS of -kr0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.13%.

Which hedge fund is a major shareholder of Isofol Medical AB?

Currently, no hedge funds are holding shares in SE:ISOFOL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Isofol Medical AB

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.